GB0517329D0 - Stimulation of neurogenesis - Google Patents

Stimulation of neurogenesis

Info

Publication number
GB0517329D0
GB0517329D0 GBGB0517329.9A GB0517329A GB0517329D0 GB 0517329 D0 GB0517329 D0 GB 0517329D0 GB 0517329 A GB0517329 A GB 0517329A GB 0517329 D0 GB0517329 D0 GB 0517329D0
Authority
GB
United Kingdom
Prior art keywords
neurogenesis
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0517329.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to GBGB0517329.9A priority Critical patent/GB0517329D0/en
Publication of GB0517329D0 publication Critical patent/GB0517329D0/en
Priority to PCT/GB2006/050244 priority patent/WO2007023310A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
GBGB0517329.9A 2005-08-25 2005-08-25 Stimulation of neurogenesis Ceased GB0517329D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0517329.9A GB0517329D0 (en) 2005-08-25 2005-08-25 Stimulation of neurogenesis
PCT/GB2006/050244 WO2007023310A2 (en) 2005-08-25 2006-08-18 Stimulation of neurogenesis with help of alk inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0517329.9A GB0517329D0 (en) 2005-08-25 2005-08-25 Stimulation of neurogenesis

Publications (1)

Publication Number Publication Date
GB0517329D0 true GB0517329D0 (en) 2005-10-05

Family

ID=35198339

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0517329.9A Ceased GB0517329D0 (en) 2005-08-25 2005-08-25 Stimulation of neurogenesis

Country Status (2)

Country Link
GB (1) GB0517329D0 (en)
WO (1) WO2007023310A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2975024T (en) 2009-06-10 2018-05-14 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
EP3698788A1 (en) 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
KR101582852B1 (en) * 2012-05-24 2016-01-07 서울대학교 산학협력단 Therapeutics for the treatment of neurodegenerative diseases mediated by Tau proteins
CA3077553C (en) 2012-09-25 2022-08-02 Chugai Seiyaku Kabushiki Kaisha Ret inhibitor
KR102412321B1 (en) 2014-04-25 2022-06-22 추가이 세이야쿠 가부시키가이샤 Preparation containing tetracyclic compound at high dose
US9714229B2 (en) 2014-04-25 2017-07-25 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
TWI765410B (en) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 Use of amorphous body of tetracyclic compound
EP3246047A4 (en) 2015-01-16 2018-08-22 Chugai Seiyaku Kabushiki Kaisha Combination drug
TWI825163B (en) 2018-09-04 2023-12-11 日商中外製藥股份有限公司 Method for producing tetracyclic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) * 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
SG145749A1 (en) * 2003-08-15 2008-09-29 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2007023310A3 (en) 2007-08-23
WO2007023310A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
ZA200707639B (en) Methods of decreasing calcification
GB0517329D0 (en) Stimulation of neurogenesis
GB0504206D0 (en) Combination therapy
HK1161122A1 (en) Use of 24-norudca 24-norudca
GB0509052D0 (en) Combination therapy
ZA200709627B (en) Combination therapy
GB0507003D0 (en) Therapeutic
GB0518720D0 (en) Therapeutic combination
EP1931370A4 (en) Use of des-aspartate-angiotensin i
GB0501655D0 (en) Therapeutic use
IL180709A0 (en) Treatment of tumours
GB0517199D0 (en) Stimulation of neurogenesis
EP1871404A4 (en) Treatment of asthma
GB0517025D0 (en) Sexual stimulator
GB0518003D0 (en) Treatment of hepatatis c
HU0400952D0 (en) Treatment of anus-cancer
TJ20050863A (en) The way of narcotism treatment
IL233202A0 (en) Transcrnial magnetic stimulation
GB0508411D0 (en) Treatment of tumours
GB0417728D0 (en) Massager
GB0412138D0 (en) Definition of zeroclick
ZA200703882B (en) Treatment of tumours
GB0502949D0 (en) Combination therapy
GB0513778D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)